Improving Safety in Phase I Trials - Planning Your Early Phase Development?

Posted:
24
April 2007

Join Richmond Pharmacology at Europe's leading Exploratory Clinical Development Congress13-16 May 2008, Earls Court Conference Centre, LondonAs the UK's largest Early Phase CRO, uniquely based in 2 acute NHS teaching hospitals, Richmond Pharmacology Ltd is proud to be an Associate Sponsor of the upcoming Exploratory Clinical Development Congress.Dr. Jorg Taubel, Managing Director of RPL, will be presenting on Day One, 14th May at 10.30am, on "Managing Risk in Early Development" and as an experienced trialist will be part of the panel discussion on "Improving the Safety of Phase I trials".We are delighted to be able to offer you a 15% discount on any delegate packages to attend this conference - please see below for details.In 2008, early clinical development remains at a critical stage. The transition to First In Man has crucial regulatory, scientific and operational issues that need to be confronted head on in order to avoid high costs and high profile product failures. Safety concerns continue to dominate and following recommendations from the ESG Working Group, the ABPI has revised its guidelines for Phase I trials.The second Exploratory Clinical Development Congress will address the critical issues in achieving seamless First In Man studies and will also provide advice on how to conduct effective studies that allow you to make the right decision early on in clinical development.Topics to be addressed at the 2008 Congress include:

  • Improving the safety of Phase I Trials - Where are we now?
  • Creating a smooth transition between preclinical and first use in man
  • Enhanced Phase I strategies
  • Managing risk in early development
  • Choosing the right dosage form
  • Biomarkers in early development
  • QT in Phase I
  • Protocol design for Phase I trials
  • The role of experimental medicine
  • Translational medicine and the rational design of exploratory studies

15% discount on attendance at this conference - If you wish to accept this offer, please contact Health Network Communications directly on: +44(0)20 7608 7056 or email: kwilliams@healthnetworkcommunications.com, quoting Richmond Pharmacology.We will be exhibiting on Stand 2 and would like to extend a warm invitation to join us on the stand to discuss your upcoming Early Phase outsourcing requirements.We look forward to meeting you at the Congress,Best regards,Dr. Jorg Taubel MFPM, MDManaging Director

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more